Repaglinide is a blocker of the ATP-sensitive potassium channel Kir6 with hypoglycemic activity.1 Clinically useful antidiabetic agent. It displays 30-fold selectivity for pancreatic Kir6.2/SUR1 over cardiac Kir6.1/SUR2B and Kir6/SUR2A channels.2 Repagli
* VAT and and shipping costs not included. Errors and price changes excepted